作者
Sander Kelderman, Bianca Heemskerk, Harm Van Tinteren, Rob RH Van Den Brom, Geke AP Hospers, Alfonsus JM Van Den Eertwegh, Ellen W Kapiteijn, Jan Willem B De Groot, Patricia Soetekouw, Rob L Jansen, Edward Fiets, Andrew JS Furness, Alexandra Renn, Marcin Krzystanek, Zoltan Szallasi, Paul Lorigan, Martin E Gore, Ton NM Schumacher, John BAG Haanen, James MG Larkin, Christian U Blank
发表日期
2014/5
期刊
Cancer Immunology, Immunotherapy
卷号
63
页码范围
449-458
出版商
Springer Berlin Heidelberg
简介
Introduction
Ipilimumab, a cytotoxic T lymphocyte-associated antigen-4 blocking antibody, has improved overall survival (OS) in metastatic melanoma in phase III trials. However, about 80 % of patients fail to respond, and no predictive markers for benefit from therapy have been identified. We analysed a ‘real world’ population of patients treated with ipilimumab to identify markers for treatment benefit.
Methods
Patients with advanced cutaneous melanoma were treated in the Netherlands (NL) and the United Kingdom (UK) with ipilimumab at 3 mg/kg. Baseline characteristics and peripheral blood parameters were assessed, and patients were monitored for the occurrence of adverse events and outcomes.
Results
A total of 166 patients were treated in the Netherlands. Best overall response and disease control rates were …
学术搜索中的文章
S Kelderman, B Heemskerk, H Van Tinteren… - Cancer Immunology, Immunotherapy, 2014